Orca Bio

We are thrilled to welcome Dr. Bijan Nejadnik to Orca Bio as Chief Medical Officer. With decades of experience bridging complex clinical innovation with successful global regulatory outcomes, Dr. Nejadnik joins us at a pivotal moment as we transition toward becoming a commercial-stage company. Read more in our press release: bit.ly/492d1CI

May is #NationalCancerResearchMonth, a time to recognize the researchers, clinicians and scientists working to advance new possibilities for patients with cancer. At Orca, we’re proud to be part of that effort by advancing high-precision cell therapies designed to help transform the future of #bloodcancer treatment. #NCRM26 #CancerResearch #CellTherapy #PatientsFirst

Advances in transplant and cell therapy are expanding our understanding of what constitutes meaningful treatment outcomes. With this in mind, we’re working to advance a high-precision approach to #CellTherapy. Learn more about our approach: bit.ly/4vVhu3N #Hematology #Oncology

Today, Orca Bio announced the U.S. FDA has granted RMAT designation to Orca-Q, marking an important milestone for the program and supporting the continued advancement of a new approach in transplant care. Read more in our press release: bit.ly/490Lhhz

Join our Senior Medical Director, Anna Pavlova, next week at the Clinical Trials in Oncology West Coast Conference for insights into navigating trial complexity, overcoming key barriers and advancing innovation in oncology. Learn more: arena-international.com/event/oncology… #ClinicalTrials #CellTherapy #GeneTherapy

Our team will be in San Diego next week to participate in #FiercePharmaEngage. Andrea Blank, Vice President of Medical Affairs, and Adria Carbo, Head of Business Development, will join this year’s program. Looking forward to joining the conversation on key issues shaping biopharma! fiercepharmaengage.com

Today, we announced that the FDA has extended the review timeline for our Biologics License Application for our investigational treatment for hematologic malignancies. Read the full press release:  bit.ly/3PJ79aD

#ICYMI: Last week, our team was on the ground in Madrid for the 52nd Annual Meeting of the @TheEBMT.​​​ ​​​​​​ It was an energizing week of scientific exchange and meaningful conversations with colleagues from across the global transplant community. We’re grateful for the opportunity to share our work and connect with so many dedicated to advancing care for patients worldwide. #EBMT26 #CellTherapy #Hematology

We look forward to joining the global transplant community at the 52nd Annual Meeting of @TheEBMT in Madrid, where Orca Bio will present clinical data highlighting our investigational high-precision cell therapy programs. Read more about our #EBMT26 presentations: lnkd.in/gMaztxMi #hematology #oncology #celltherapy #bloodcancer #BMT

This month’s #EmployeeSpotlight is Mike Hirschmann, recently promoted to Orca Bio’s Chief Commercial Officer (CCO). Mike, previously our Senior Vice President of US Commercial, joined Orca Bio from Legend Biotech and brings nearly 30 years of biotechnology and pharmaceutical expertise, with specialization in hematology/oncology and cell gene therapy. His experience launching a landmark CAR-T therapy will be invaluable at #TeamOrcaBio as we look to bring a first-of-its-kind high-precision therapy to blood cancer patients. With the potential approval of our lead investigational cell therapy on the horizon, we’re thrilled to have Mike's experience and passion at the forefront of our commercial launch readiness efforts.

We are pleased to present new data at the 2026 Tandem Meetings of @ASTCT and @CIBMTR that support the potential of our investigational high-precision cell therapy in hematologic malignancies. Read the press release for details on our data and presentations: bit.ly/4tdLmHb #Tandem26 #Oncology #Hematology #CellTherapy

A blood cancer diagnosis can turn life upside down – for patients and the people who love them. On #WorldCancerDay, we’re united in support of the blood cancer community and committed to our mission of transforming the lives of patients through high-precision cell therapies.  For information and resources for patients, caregivers and providers, visit @BloodCancerUtd: bloodcancerunited.org #UnitedByUnique #BloodCancer

Attending the 2026 Tandem Meetings of @ASTCT and @CIBMTR next week in Salt Lake City? We’d love to connect at Booth #101. Learn more about our presentations highlighting new data and meaningful findings across our pipeline of investigational allogeneic T-cell immunotherapies for the treatment of multiple hematological malignancies: ow.ly/M6BO50Y59x7 #Tandem26 #hematology #oncology #cancerresearch #celltherapy

Orca Bio looks forward to joining the transplant community at the 2026 Tandem Meetings of the @ASTCT and @CIBMTR where we will present new clinical data on our investigational high-precision cell therapies. Read more about our nine #Tandem26 presentations in our press release: bit.ly/45lhcYk #hematology #oncology #celltherapy #bloodcancer #cancerresearch

This week, Orca Bio's CFO and Head of Strategy, Josh Murray, will join industry leaders and investors on a Fierce JPM Panel to discuss how biotech companies are navigating today’s funding environment, evaluating public versus private pathways and positioning for long-term growth as market conditions evolve. Looking forward to an insightful discussion! To register, visit: fiercejpmweek.com #Biotech #FierceJPMWeek #FierceJPM2026

Today, Orca Bio announced $250M in aggregate financing to support launch readiness preparations in addition to new clinical program advancements. Read more in our press release: bit.ly/4syGhcd #hematology #oncology #celltherapy

Next week, Orca Bio’s co-founder and CEO, Nathaniel Fernhoff, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. We look forward to engaging with the #biotech investor community and other industry leaders to highlight recent progress and preview anticipated milestones for the year ahead. More details on our presentation on Jan. 12 at 7:30 AM PT: bit.ly/44Yj1KF #JPM26 #bloodcancer #oncology #hematology #celltherapy

As we close out one of the most pivotal years in Orca Bio’s history, we’re proud of the momentum we’ve built across the organization. We look forward to carrying this energy into the new year, staying focused on our mission and the patients who inspire us every day. Together, we can make 2026 a year that truly changes lives. #celltherapy #hematology #oncology #patientsfirst